Simone Lubrano, PhD My research aims to understand why some melanomas stop responding to treatments over time and to identify new ways to make these therapies more effectiv...
Joanna Pozniak, PhD My current research focuses on understanding how individual patients’ tumors react to immune-centered therapies (immunotherapy). To capture the full p...
Dan Erkes‘s Abstract Melanoma is the most lethal skin cancer, leading to an estimated 8,290 deaths and 100,640 new cases in 2024. Melanoma was traditionally ...
Daniel Hirschhorn‘s Abstract Immunotherapy has greatly improved survival for people with melanoma, but many patients also experience harmful side effects wh...
Kenneth Hu‘s Abstract Immunotherapies including immune checkpoint blockade (ICB) have seen remarkable success in the clinic. Unfortunately, many patients with late-st...
Emily Bernstein‘s Abstract Melanoma is the most lethal skin cancer, and the success of current therapies remains limited. To better tailor melanoma treatments, we m...
Lisa Cannon-Albright‘s Abstract Analysis of large families with more disease than expected has been shown to be a powerful way to identify cancer predisposition g...
Mathieu Desaunay‘s Abstract Skin cancer is one of the most common types of cancer, with melanoma being the deadliest form. In the United States, approximately 104,9...
Mona Foth‘s Abstract Acral and mucosal melanomas(A&MM) are rare but aggressive types of melanoma, making up less than 5% of all cases. Unlike the more common typ...
Thorsten Mempel‘s Abstract While immunotherapy has greatly improved the survival for patients with melanoma of the sun-exposed skin, especially for those with adva...
Hee Won Yang‘s Abstract Melanoma is an aggressive type of skin cancer known for its rapid spread and frequent resistance to current treatments. Many advanced melanoma...
Craig Ceol‘s Abstract The use of immunotherapies has revolutionized treatment for late-stage melanoma patients. These therapies have extended survival for many patien...
Nov 22, 2025 PT
